Episode 39 — how NGS is transforming cancer care through precision medicine, and what still stands in the way: insurance coverage gaps, clinical workflow friction, and the slow march from test availability to test adoption.

TPM Podcast #46 — liquid biopsy, multi-omics, and AI are reshaping personalized care, but the diagnostics business model still hinders the field. A conversation about what it will take to make these technologies accessible at scale.

A live(ish) conversation recorded at AGBT 2025 — covering the state of play in next-generation sequencing: where the market stands, what the conference signaled, and what comes next for the tools and diagnostics layer of genomics.

A conversation with Theral Timpson about how recent economic pressures have exposed fundamental flaws in the life science tools business model — and why the foundational pricing assumptions in the sector need to be rethought from the ground up.